CSI Market
Sign In | Register

Ptc Therapeutics inc (PTCT) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PTCT quarterly Cash Flow →
Cash flow data covering Ptc Therapeutics inc–Dec 31 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income682.64
Depreciation & amortization38.82
Amortization of Other Assets1.22
Increase (Decrease) in Deferred Policy Acquisition Costs0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability-0.80
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-53.90
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.29
Share-based Compensation74.55
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized3.38
Lease Cost Non Cash-
Unrealized Gain Losson Convertible Securities-
Operating Lease Cost Non Cash-
Finance Lease Cost Non Cash-
Settlement Of Deferred And Contingent Consideration-
Operating Lease Right Of Use Asset Amortization Expense7.47
Finance Lease Right Of Use Asset Amortization-
Noncash Royalty Revenue Sale Of Future Royalties-228.57
Noncash Interest Expense Liability Related To Sale Of Future Royalties215.16
Clearpoint Equity Investment Fvni Unrealized Gain Loss-5.73
Debt Securities Available For Sale Unrealized Gain Loss-
Increase Decrease In Contract With Customer Liability1.02
Increase Decrease In Contingent Consideration-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Receivables-10.15
Increase (Decrease) in Accounts Payable and Accrued Liabilities71.74
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets-34.18
Other Working Capital-17.40
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-34.36
Discontinued operations0.00
Net Cash flow from Operating Activities711.20
Investing Activities
Capital Expenditures-300.01
Sale of Capital Items0.07
Short-term Investments Proceeds842.70
Short-term Investments Acq.-1,417.16
Payments for (Proceeds from) Derivative Instrument, Investing Activities0.00
Payments To Acquire Convertible Debt Investment-
Proceeds From Sale And Maturity Of Clearpoint Equity Investment12.41
Proceeds From Sale Of Priority Review Voucher-
Proceeds From Principal Payment Of Clearpoint Convertible Debt Security-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-861.98
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Proceeds from (Payments for) in Securities Sold under Agreements to Repurchase0.00
Issuances / -repurchases of Comm. Stock99.05
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-801.66
Sale Of Stock Consideration Received On Transaction-
Proceeds From Issuance Public Offering-
Change In Unrealized Gain Loss On Marketable Securities-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents795.32
Payments On Deferred Consideration Obligation-
Payment Of Finance Lease Principal-1.61
Proceeds From Sale Of Future Royalties240.00
Finance Lease Principal Payments-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities331.09
Effect of exchange rate on cash flow22.71
Discontinued operations0.00
Free Cash Flow411.25
Total Cash Flow203.02
4 historic quarters locked

Sign in to unlock the full Ptc Therapeutics inc cash flow history.

Sign In Create Free Account

About Ptc Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-017575

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License